The Clorox Company (CLX) Q4 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2025 earnings summary
8 Jul, 2026Executive summary
Fiscal year 2025 ended with strong margin and adjusted EPS growth, despite weaker than expected top-line growth and a challenging second half marked by market volatility and macroeconomic uncertainty.
Retailer inventory build ahead of a major ERP implementation temporarily boosted shipments and sales, creating significant timing noise between FY25 and FY26.
Digital transformation advanced with the completion of a major U.S. ERP implementation, expected to unlock long-term productivity and digital capabilities.
Execution challenges in certain segments, notably Kingsford and Cat litter, impacted share performance, though brand health and household penetration remained strong.
Consumer categories slowed in the back half of the year due to macroeconomic uncertainty, with sluggish consumption trends expected to persist into early FY26.
Financial highlights
Q4 organic sales growth was about 8%, with ERP shipments contributing 13–14 points, but underlying sales declined approximately 5% year-over-year.
Q4 gross margin was 46.5%, up 150 basis points due to ERP shipments; full-year gross margin rose 220 bps to 45.2%.
Q4 diluted EPS increased 55% to $2.68; adjusted EPS up 58% to $2.87, with ERP shipments adding $0.85–$0.95.
FY25 adjusted EPS up 25% to $7.72; net cash from operations was $981M, up 41% year-over-year.
Price/mix was negative 4% in Q4, driven by one-time trade spending adjustments and lapping prior year merchandising events.
Outlook and guidance
FY26 net sales expected to decline 6–10% year-over-year, with organic sales down 5–9% due to ERP shipment reversal.
FY26 organic sales growth guidance (excluding ERP impact) is -1% to +2%, with gross margin expected to be flat to down 100 bps and Adjusted EPS guidance of $5.95–$6.30 (down 23–18%).
ERP-related inventory build in FY25 will reverse in FY26, creating a 3.5–4% headwind to reported sales and impacting Q1 and Q4 most significantly.
Innovation pipeline and net revenue management initiatives are expected to drive sequential improvement, especially in the back half of FY26.
Tariff headwinds of ~$40 million are anticipated, to be offset by sourcing changes, productivity, and targeted pricing.
Latest events from The Clorox Company
- Digital transformation and IGNITE strategy accelerate growth, margin expansion, and innovation.CLX
Consumer Analyst Group of New York Conference 20259 Jul 2026 - Net sales fell 19% and gross margin dropped to 41.7% amid ERP transition impacts.CLX
Q1 20269 Jul 2026 - $2.25B acquisition expands health & hygiene leadership, driving $50M in synergies.CLX
M&A announcement9 Jul 2026 - Q2 FY2026 sales and earnings declined, with major acquisitions and ongoing cost pressures.CLX
Q2 20268 Jul 2026 - ERP stabilization, innovation, and GOJO integration drive growth amid leadership transition.CLX
23rd annual dbAccess Global Consumer Conference3 Jun 2026 - GOJO acquisition closed as Q3 sales stayed flat and margin pressure persisted amid cost headwinds.CLX
Q3 20264 May 2026 - ERP completion, innovation, and GOJO acquisition drive growth and margin expansion plans.CLX
Citi’s 2026 Global Consumer & Retail Conference 20269 Mar 2026 - Digital and portfolio advances, plus GOJO acquisition, drive growth and health & hygiene scale.CLX
Consumer Analyst Group of New York Conference (CAGNY) 202619 Feb 2026 - Margin expansion and portfolio reshaping drive FY24 results and FY25 outlook.CLX
Q4 20242 Feb 2026